The future of EU agencies based in London will be part of tomorrow’s EU-27 summit, an issue that could erode the unity that European leaders want to showcase before the divorce talks with the UK begin.
Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
The future location of the two European Union agencies based in London will be a matter for Brexit negotiations, the British government's Brexit department said yesterday (17 April), but EU officials said there was no doubt they would be moved.
Patient organisations warned the European Council yesterday (12 April) to be “vigilant” in the relocation of the European Medicines Agency (EMA), as well as avoid unnecessary delays that may cause disruptions in healthcare.
Controls on EU immigration played a key role in the Brexit vote. However, the UK government now says that it wants to protect the free movement of researchers and talent, which are crucial for the life sciences sector. EURACTIV.com reports from Lyon.
The criteria regarding the relocation of the European Medicines Agency (EMA) from London after the Brexit vote should not be political, Danish and Greek officials told Euractiv.com on Monday (20 February).
In the aftermath of the Brexit vote, Rome and Madrid are leading the race to gain the right to host influential EU agencies, while Croatia, Bulgaria, Cyprus, Romania and Slovakia could remain empty-handed.
The UK's pharmaceutical regulator would lose influence over the European Medicines Agency (EMA) if Britons vote to leave the EU in a June referendum. As a result, it could well consider aligning itself with its US equivalent, sector advisors have told EURACTIV.com.
Denmark's pharmaceutical industry is going head-to-head with its Swedish counterpart by arguing Denmark should be the new home of the European Medicines Agency (EMA) if Britons vote to leave the European Union in a June referendum.
Vytenis Andriukaitis, Commissioner-designate for Health and Food Safety, told MEPs today (30 September) during his confirmation hearing that the EU would not lower its safety standards as result of negotiations over the Transatlantic Trade and Investment Partnership (TTIP).
The Chief Medical Officer (CMO) for England, Professor Dame Sally Davies, has pointed to the danger of bacteria's growing resistance to antibiotics, saying an EU funded medical initiative may be the solution to the problem.
The OECD is urging its member governments to harmonise their clinical trial approval processes, citing a decline in the pharmaceutical sector in the EU, where the number of applications for clinical trials fell 25% between 2007 and 2011.
Jim Murray argues that the European Commission's health and consumers department (DG SANCO) must take the lead in ensuring the European Medicines Agency's (EMA) independence in approving drugs and medicines.